Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 5 15 SULFITE FREE W ELECT IN DEXTROSE 15 W CALCIUM IN PLASTIC CONTAINER versus EPANOVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 5 15 SULFITE FREE W ELECT IN DEXTROSE 15 W CALCIUM IN PLASTIC CONTAINER versus EPANOVA.
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER vs EPANOVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX E 5/15 is a parenteral nutrition solution that provides essential amino acids, electrolytes, and dextrose for intravenous use. Amino acids serve as building blocks for protein synthesis, dextrose provides calories for energy metabolism, and electrolytes maintain fluid and electrolyte balance. Calcium is essential for bone mineralization, neuromuscular function, and enzyme activation.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Intravenous infusion. Typical adult dose: 1.5–2.0 L/day of CLINIMIX E 5/15 (providing 75–100 g amino acids and 225–300 g dextrose per day) administered via central line; rate determined by glucose tolerance and fluid status.
4 g orally once daily as 4 capsules of 1 g each with food.
None Documented
None Documented
Components have variable half-lives: amino acids ~0.5-1 h; dextrose ~2-4 h; electrolytes depend on renal function. Terminal half-life not applicable as a mixture.
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Renal excretion of amino acids and electrolytes; dextrose is metabolized to CO2 and water, with minimal renal excretion. Biliary/fecal elimination is negligible (<2%).
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution